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ABSTRACT
Background: Small bowel capsule endoscopy (SBCE) is a 
very important tool in the diagnosis and monitoring of Crohn’s 
disease (CD). The Lewis score (LS) and Capsule Endoscopy 
Crohn’s Disease Activity Index (CECDAI) are used to quantify and 
standardize inflammatory activity observed in the SBCE.
Aim: To evaluate the correlation between the LS and CECDAI 
scores and inflammation biomarkers (C-reactive protein [CRP] 
and erythrocyte sedimentation rate [ESR]). A secondary goal was 
to define thresholds for CECDAI based on thresholds already 
established for LS.
Methods: This was a retrospective study of 110 patients 
with suspect or known CD, with involvement of small bowel. 
Linear regression was used to calculate thresholds of CECDAI 
corresponding to the thresholds already established for LS. A 
Pearson correlation (r) was used to calculate the correlation between 
the LS and CECDAI scores and biomarker levels. Only patients with 
exclusive involvement of the small bowel were selected (n = 78). 
Results: A moderate correlation was found between the 
endoscopic scores (r = 0.59, p < 0.001). CECDAI scores of 
5.57 and 7.53 corresponded to scores of 135 and 790 in LS, 
respectively. There was a statistically significant correlation between 
CRP and the LS (r = 0.28, p = 0.014) and CECDAI (r = 0.29, p = 
0.009). There was also a significant correlation between ESR and 
CECDAI (r = 0.29, p = 0.019), but not with LS. 
Conclusion: There is a moderate correlation between the two 
scores. This study allowed the calculation of thresholds for CECDAI 
based on those defined for LS. We found a weak correlation 
between SBCE endoscopic activity and inflammatory biomarkers. 
Key words: Lewis score. Capsule Endoscopy Crohn’s Disease 
Activity Index. Small bowel capsule endoscopy. Inflammatory 
biomarkers.
INTRODUCTION 
Since its approval by the Food and Drug Administration 
(FDA) in 2001, small bowel capsule endoscopy (SBCE) 
has rapidly become the state of the art technique for small 
bowel imaging (1). It allows a non-invasive evaluation 
of the mucosa with a higher sensitivity for inflammatory 
lesions than other non-invasive diagnostic modalities such 
as MRI or CT scan (2-4), although it does not enable the 
assessment of small bowel wall thickness or extraluminal 
involvement (2,3). 
Crohn’s disease (CD) is an idiopathic inflammatory con-
dition that may affect any segment of the gastrointestinal 
tract and affects the small bowel in up to 66% of patients 
with the disease (5). This disease arises from the interaction 
between genetic and environmental factors, with periods of 
remission and relapse requiring close clinical management 
for therapy and disease monitoring (5). The diagnosis of 
this condition is based on the clinical presentation (chron-
ic diarrhea, abdominal pain, weight loss or growth fail-
ure), in addition to extra intestinal manifestations (such as 
fever, arthritis/arthralgia, pyoderma gangrenosum, perianal 
disease) and/or altered laboratory based values (anemia, 
inflammatory markers), gastrointestinal endoscopy and 
histology data and/or abnormal imaging (6). 
One of the main indications for SBCE is suspected 
Crohn’s (7) disease after a negative ileocolonoscopy (8). 
SBCE may also be used to assess disease extent and activity 
in patients with established CD and may influence patient 
management and prognosis (4,9-11). Mucosal healing is an 
emerging concept in CD management as a therapeutic goal, 
which has been associated with a good prognosis (12). There 
is no validated definition for this endpoint (2) but it has been 
associated with a lower relapse and hospitalization rate and 
a reduction in the prevalence of fistulae and surgery (13-15). 
Several recent studies have evaluated the ability of SBCE 
to detect mucosal changes in patients with known CD. The 
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majority of studies concluded that SBCE was an effective 
and safe tool for the evaluation of mucosal healing in assess-
ing small bowel treatment response during follow up (16-
19). LS and the CECDAI are two index scores developed 
and validated to standardize the extent and severity of small 
bowel inflammation on SBCE (20,21). 
Biomarkers have been thoroughly evaluated in Crohn’s 
disease and are useful tools for diagnosis, assessment of 
disease activity, prediction of relapse, risk of complications 
and monitoring of the response to therapy (22). C-reactive 
protein (CRP) and erythrocyte sedimentation rate (ESR) are 
standard laboratory surrogates of the acute phase inflamma-
tory activity (6). The aim of this study was to evaluate the 
correlation between SBCE scores (LS and CECDAI) and 
inflammatory serum biomarkers (CRP and ESR). A second-
ary aim was to define the thresholds for CECDAI based on 
the thresholds already established for LS.
METHODS
A retrospective cohort study was performed that included patients 
with suspected or known CD who underwent consecutive SBCE. All 
patients had an ileocolonoscopy as the first endoscopic diagnostic 
procedure. Patients taking aspirin or non-steroid anti-inflammatory 
drugs discontinued the medication at least four weeks before the 
SBCE examination (2). Prior to SBCE, patients were on a clear 
liquid diet for 24 hours and fasted for 12 hours. The SBCE videos 
were reviewed and the LS was calculated by one single experiment 
investigator (more than 100 SBCE sequence reviews) using the soft-
ware application in the RAPID Reader® v.8 workstation. The LS 
was calculated by dividing the small bowel transit time (SBTT) into 
three tertiles. A subscore of inflammation was calculated for each 
tertile based on the characteristics of villous edema and ulceration. 
In those patients where the capsule did not reach the cecum, small 
bowel tertiles were determined based on the last small bowel image. 
The final score was the sum of the tertile with the highest score and 
the stenosis score, rated for the whole examination (20). Although 
there is no automatic software available, the CECDAI (Niv score) 
was calculated by dividing the small bowel in half on the basis of 
small bowel transit time of the capsule and each segment was scored 
individually. CECDAI consists of three parameters: inflammation 
score (score 0-5; erythema, hyperemia and edema, denudation, 
nodularity, aphthae, erosion, ulcer and bleeding), extent of disease 
(score 0-3; focal, patchy, and diffuse) and narrowing score (score 
0-3; single-passed, multiple-passed and obstruction) (21). All three 
parameters were calculated separately for the proximal and distal 
segments of the small bowel and the total CECDAI score was cal-
culated by adding the score of both segments (21). 
The blood samples were collected within ± 7 days of the SBCE 
procedure (based on department protocol) and without changing 
the medication during this period. ESR was considered as elevated 
when the levels were higher than 12 mm/h and CRP, when levels 
were over 2.90 mg/l in accordance with the reference values used 
in our hospital.
Statistical analysis was performed with SPSS® version 22.0 
(IBM, Armonk, New York, USA). The categorical variables are pre-
sented as frequencies and percentages, and continuous variables are 
presented as means and standard deviations. All reported p values are 
two-tailed, with a p value of 0.05 indicating statistical significance. 
A linear regression (model Y = a + bX, 95% CI) was used (the same 
methodology used by Koulaouzidis A et al.) to define the thresholds 
for CECDAI (corresponding to those defined for LS) (23). Pear-
son’s correlation was used to calculate the correlation between the 
inflammation scores and inflammatory biomarkers (CRP and ESR). 
This analysis only included patients with isolated small bowel CD. 
The Evans classification (1996) was used to define the power of the 
correlation (0.0-0.19 very weak; 0.2-0.39 weak; 0.4-0.59 moderate; 
0.6-0.79 strong; 0.8-1 very strong) (24). The Student’s t-test was 
used to test the differences between the mean of the biomarker values 
according to the severity of inflammatory activity. 
RESULTS
One hundred and ten consecutive patients were enrolled 
and all patients fulfilled the inclusion criteria. The mean 
age was 35.2 ± 13.1 years and 67 were females (60.9%). 
The patients with isolated small bowel involvement cor-
responded to 70.9%. There was involvement of both the 
small bowel and colon in 29.1% of patients and there was 
involvement of the upper gastrointestinal tract in 18.2% 
of the cases. CRP mean levels were 9.60 ± 16.8 mg/l, and 
ESR levels were 17.2 ± 13.7 mm. The mean LS was 1,108 
± 1,361 and CECDAI was 8.11 ± 6.16. The mean time of 
SBTT was 305 ± 133 min (Table 1). 
A moderate correlation between the LS and the CEC-
DAI was observed (r = 0.59, p < 0.001) (Fig. 1). In our 
cohort, CECDAI thresholds of 5.57 and 7.53 corresponded 
to LS values of 135 and 790, respectively. To calculate 
the association between inflammatory biomarkers and 
the SBCE scores, a subanalysis was performed only with 
patients (n = 78) with isolated small bowel CD. In this 
group, the mean age was 35.1 ± 12.5 years and 46 were 
females (59%). The mean CRP was 9.88 ± 19.4 mg/l and 
ERS was 16.8 ± 14.1 mm. The mean CECDAI was 7.49 ± 
5.60 and LS was 898 ± 1,141 (Table 1).
There was a weak but statistically significant correla-
tion between CRP and the LS (r = 0.28, p = 0.014) and 
the CECDAI (r = 0.29, p = 0.009) (Figs. 2 and 3). There 
was also a correlation between ESR and the CECDAI (r 
= 0.29, p = 0.019) (Fig. 4), and no correlation was found 
between ESR and the LS. Patients with a CECDAI ≥ 7.53 
had significantly higher values of serum inflammatory bio-
markers than patients with CECDAI < 7.53 (CRP: 4.36 vs 
17.0 mg/l, p = 0.004; ESR: 13.4 vs 20.9 mm, p = 0.032). 
CRP values were also significantly higher (CRP: 20.7 vs 
5.07 mg/l, p = 0.001) in patients with LS ≥ 790, although 
this was not observed for ESR (Fig. 5). 
DISCUSSION
The assessment of the distribution and the degree of 
small bowel inflammation is a critical point in the manage-
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which have been previously described (23). In our study 
we found the cut-off values of 5.57 and 7.53 corresponding 
to LS values of 135 and 790, respectively. This difference 
may be explained by the larger number of patients includ-
ed in our study and by the fact that our cohort had higher 
LS mean values, probably due to a higher inflammato-
ry activity. It is also important to highlight that CECDAI 
takes into account erythema, hyperemia, denudation and 
nodularity, and these aspects are not included in LS, which 
may explain the higher final CECDAI score.
A statistically significant correlation was demonstrated 
between the two endoscopic scores, which is in line with 
a previous published study (23). These scores provide a 
Fig. 1. Correlation between the inflammatory scores of the SBCE and the 
Lewis score (LS) and Capsule Endoscopy Crohn’s Disease Activity Index 
(CECDAI) values. Linear regression of CECDAI and LS, 95% confidence 
interval.
Fig. 2. Correlation between C-reactive protein (CRP) and Lewis score (LS).
Table 1. 
Total population Isolated SB CD
n 110 (100%) 78 (100%)
Gender 
 Male
 Female 
43 (39.1%)
67 (60.9%)
32 (41%)
46 (59%)
Age, mean (SD), yr 35.2 ± 13.1 35.1 ± 12.5
Involvement SB 78 (70.9%) -------------
Involvement SB + colon 32 (29.1%) -------------
Involvement of superior 
gastrointestinal tract
20 (18.2%) -------------
Montreal classification 
Age at diagnosis:
 A1
 A2
 A3
Location:
 L1 
 L3 
 L4 + L3 
Behavior:
 B1
 B2
 B3 
Perianal disease 
8 (7.3%)
77 (70%)
25 (22.7%)
78 (70.9%)
12 (10.9%)
20 (18.2%)
97 (88.2%)
11 (10%)
2 (1.8%)
5 (4.5%)
-------------
-------------
-------------
-------------
-------------
-------------
70 (89.7%)
6 (7.7%)
2 (2.6%)
2 (2.6%)
CRP, mean (SD) mg/l 9.60 ± 16.8 9.88 ± 19.4
ERS, mean (SD) mm 17.2 ± 13.7 16.8 ± 14.1
LS, mean (SD) 1,108 ± 1,361 898 ± 1,141
CECDAI, mean (SD) 8.11 ± 6.16 7.49 ± 5.6
Small bowel transit time, 
mean (SD) min
305 ± 133 307 ± 125
SBCE:
 Complete
 Incomplete
94 (85.5%)
16 (14.5%)
69 (88.5%)
9 (11.5%)
SB: Small bowel; CD: Crohn’s disease; LS: Lewis score; SD: Standard devia-
tion; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; CECDAI: 
Capsule Endoscopy Crohn’s Disease Activity Index; SBCE: Small bowel capsule 
endoscopy.
ment of CD patients. The LS is based on the number and 
extent of segments of villous edema, aphthae and ulcers 
or the presence of stenosis (20). Inflammatory activity is 
classified into three degrees of severity: a) a score of < 135 
is compatible with no change or clinically insignificant 
mucosal changes; b) a score of ≥ 135 to 790 is defined as 
mild mucosal disease; and c) a score of ≥ 790 is defined 
as moderate to severe disease (20). CECDAI is based on 
the assessment of three parameters: inflammation, disease 
extent and luminal narrowing (21). No clear threshold of 
inflammation has been consistently defined for CECDAI 
so far (25). However, cut-off values of 3.8 and 5.8 corre-
spond to the LS thresholds of 135 and 790, respectively, 
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reproducible methodology for the interpretation and esti-
mation of endoscopic activity of inflammatory disease. 
Although both the LS and the CECDAI have been validat-
ed in the setting of Crohn’s disease, due to the non-specific 
characteristics of small bowel inflammatory lesions, the 
inflammatory activity is graded regardless of its etiology 
(20,21).
There is an important need for accurate biomarkers to 
accurately assess disease activity and potentially predict 
relapses. The ideal marker should be specific and sensitive, 
reproducible, rapid, easy to perform, readily available and 
cost effective (22). CRP and ESR are widely used as sur-
rogate markers in CD for diagnosis and therapeutic moni-
toring (26). CRP is a pentameric protein consisting of five 
monomers and is one of the most important acute phase 
proteins in humans (22,27). It is produced by hepatocytes 
in low quantities and its production increases under the 
influence of IL-6, TNF-α and IL-1β with an inflamma-
tion stimulus (22,27). This surrogate has a short half-life 
and is often up-regulated within hours after the onset of 
inflammation, and rapidly decreases after resolution of the 
stimulus (22,27). ESR is an indirect measure of inflam-
mation, corresponding to the rate at which erythrocytes 
migrate through the plasma. An increase in plasma viscos-
ity occurs due to the production of acute phase response 
proteins (22,27). 
A correlation was found between CRP and the two endo-
scopic scores. With regard to ERS, there was a correlation 
with the CECDAI but not with the LS. Higher values of 
CRP and ERS were found in patients with a CECDAI score 
≥ 7.53 compared with patients with CECDAI scores < 7.53 
(CRP: 4.36 vs 17.0 mg/l, p = 0.004; ERS: 13.4 vs 20.9 mm, 
p = 0.032). CRP values were higher in patients with LS ≥ 
790 (CRP: 20.7 vs 5.07 mg/l, p = 0.001) as compared to 
those with an LS score < 790. These biomarkers together 
with inflammatory scores of SBCE are currently used for 
diagnosis, treatment decisions and therapy stratification. 
The new therapeutic endpoint of CD is achieving muco-
sal healing. Several studies have established a poor correla-
tion of clinical symptoms with endoscopic inflammation 
(28). A recent study by Kopylov U et al. of 55 patients 
showed that 92.9% were in clinical remission and 40.4% 
were in clinical-biomarker remission; likewise, a moderate 
to severe small bowel inflammation by SBCE was present 
in 21.1% and 4.7% of patients, respectively. Only 13.5% 
of patients were in deep remission, which was defined by 
the absence of symptoms, CDAI < 150, mucosal healing 
as the restoration of normal mucosal appearance and a 
Fig. 3. Correlation between C-reactive protein (CRP) and Capsule Endos-
copy Crohn’s Disease Activity Index (CECDAI).
Fig. 4. Correlation between erythrocyte sedimentation rate (ESR) and 
Capsule Endoscopy Crohn’s Disease Activity Index (CECDAI). 
Fig. 5. Correlation between erythrocyte sedimentation rate (ESR) and 
Lewis score (LS).
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decrease of inflammatory biomarkers (17). This goal was 
associated with an improved health related quality of life 
and a decrease of complications that required surgery and 
hospitalization (17). A prospective study by Boal Carvalho 
P et al. showed that within a population of 12 patients in 
sustained corticosteroid-free remission, 75% of patients 
had significant inflammatory activity in SBCE (29). These 
studies reinforce the importance of the evaluation of small 
bowel inflammatory activity by SBCE for the management 
and prognosis of patients with CD. 
This study verified the fact that although higher levels 
of CRP and ESR were associated with higher values of the 
inflammatory scores, the strength of the correlation was 
very low, thus highlighting the need to evaluate the status 
of the small bowel mucosa and the treatment response by 
SBCE. Due to its non-invasive nature and detailed imag-
ing, SBCE is an important technique not only for diagno-
sis but also for the follow-up and assessment of mucosal 
healing. 
Fecal calprotectin is another biomarker that has shown 
a good accuracy in the detection of endoscopic active dis-
ease (30,31). Although it has demonstrated a good correla-
tion with the inflammation of the colon, its value for the 
assessment of small bowel inflammation in IBD remains 
to be elucidated. In fact, a recent study found that even in 
the presence of large ulcers, patients with ileal CD did not 
have markedly elevated fecal calprotectin levels (32). In 
addition, calprotectin data was not available in this cohort 
as it is a recently described inflammatory biomarker and 
the study was retrospective.
To conclude, the role of SBCE and inflammatory bio-
markers in the diagnosis and management of CD is still 
evolving. Although both endoscopic scores (LS and CEC-
DAI) have been validated, no threshold of inflammatory 
activity for the CECDAI has been widely adopted. This 
study has determined the CECDAI cut-off values based 
on the thresholds defined for LS. Ideally, the small bowel 
should be assessed with a non-invasive endoscopic meth-
od such as SBCE, which has validated scores that mea-
sure inflammatory activity. This is of greater importance 
as there is a poor correlation between SBCE endoscopic 
activity and inflammatory biomarkers.
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